Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2008
Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone.
Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Utility of Vibration Perception Thresholds as a Biomarker of Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis.European journal of pain (London, England) · 2026Pooled it
- A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma.PloS one · 2010Trial
- Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010Trial
- Assessing the Efficacy of Anastomosis between Ansa Cervicalis and Facial Nerve for Patients with Concomitant Facial Palsy and Peripheral Neuropathy.Journal of personalized medicine · 2022Article
- Physical impairments, sensory disturbance, and functional ability in a cancer patient with and without chemotherapy-induced peripheral neuropathy symptoms.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Taxane-induced peripheral neuropathy: differences in patient report and objective assessment.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Article
- Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN).Frontiers in pharmacology · 2013Review
- Chemotherapy-induced peripheral neurotoxicity.Nature reviews. Neurology · 2010Review
- Sensory-motor axonal peripheral neuropathy in an advanced breast cancer patient treated with ixabepilone.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe have previously established the recommended phase II dose (RPTD) of ixabepilone as 40 mg/m(2) administered over 1 h repeated every 3 weeks with neuropathy as a cumulative dose-limiting toxicity. We expanded the cohort at the RPTD to include detailed assessment of nerve damage in these patients. We report our findings on vibration perception threshold (VPT) and neuropathy. PATIENTS AND
methodsForty-four patients were treated with a median (range) of three (1-14) cycles of ixabepilone. The VPT (5-min duration) and nerve conduction test (NCT, 10-min duration) were carried out in the office, before ixabepilone dosing, and every two cycles thereafter.
resultsNeuropathy (grade 1 and grades 2-3) was observed in 17 (38.6%) and 11 (25%) patients, respectively. The mean increase in VPT as a function of grade 0-1 versus grades 2-3 neuropathy was 0.235 +/- 0.03 versus 0.869 +/- 0.09 (P = 0.049) vibration units. The F-wave frequency and distal motor latency, as assessed using the NCT, did not correlate with clinical neurotoxicity.
conclusionThe change in VPT is observed early and likely reflects early vibration perception change. Mean change in VPT correlates with the severity of clinical neuropathy. Whether VPT change predicts onset of severe neuropathy warrants prospective testing and validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.